Brown & Brown (NYSE:BRO) Misses Q2 CY2026 Revenue Estimates
Brown & Brown (NYSE:BRO) reported Q2 CY2026 revenue of $1.68 billion, up 30.4% year over year but below analysts’ $1.72 billion estimate. Non-GAAP EPS was $1.07, matching consensus. Adjusted EBITDA was $598 million versus $603.1 million expected. The article also notes analysts expect 12-month revenue growth of 5.9%.
How this was made
The 30-second read
Why it matters
The key new datapoints are the Q2 CY2026 revenue miss ($1.68B vs $1.72B) and adjusted EBITDA miss ($598M vs $603.1M), partially offset by adjusted EPS matching ($1.07).
Market read
Traders can reassess near-term expectations given the revenue and EBITDA misses, even though EPS was in line and YoY growth was strong.
What to watch
The article does not discuss guidance, deal flow, or segment performance; traders may need those details to judge whether the revenue miss reflects temporary timing versus structural slowdown.
Background
Brown & Brown is an insurance brokerage and risk management firm; the article frames the quarter’s results versus Wall Street consensus.
Ticker impact
Brown & Brown reported Q2 CY2026 revenue of $1.68B versus $1.72B estimates, while adjusted EPS of $1.07 matched consensus.
Likely choppy trading, with downside risk if investors focus on the revenue miss and EBITDA margin/EBITDA miss rather than EPS in-line.
The article provides concrete print vs consensus (revenue and adjusted EBITDA) and notes EPS in-line, which typically dampens the reaction but still matters for brokerage valuation tied to growth and earnings quality.
Market effects
Signals insurance brokerage demand remains strong (30.4% YoY revenue growth) but with some deceleration versus recent pace.
No specific regional impact mentioned.
No explicit global macro or cross-border catalyst mentioned.
Counterpoint
The 30.4% YoY revenue growth and in-line adjusted EPS may indicate the miss is more about estimate expectations than deteriorating fundamentals.
Key entities
- companyBrown & Brown
Insurance brokerage reporting Q2 CY2026 results versus analyst consensus.

